NCT06180785

Performance Evaluation of the Biological Diagnosis of HIT

Performance Evaluation of the Biological Diagnosis of Heparin-induced Thrombocytopenia (HIT)

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 894 (estimated)
• Sponsor: University Hospital, Strasbourg, France · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Heparin-induced thrombocytopenia (HIT) is a severe complication of heparin therapy with a non-negligible incidence (estimated at 2.6% of unfractionated heparin treatments and 0.2% of low molecular weight heparin treatments). It is generally secondary to the appearance of IgG antibodies directed against the platelet factor 4 (PF4) - heparin complex. These antibodies, once bound to this complex, are likely to activate platelets: the thrombotic risk generated can be potentially fatal.

Conditions

• Heparin-induced Thrombocytopenia (HIT)

Timeline

• Start date: 2022-06-27
• Primary completion: 2023-12-01
• Completion: 2023-12-01
• First posted: 2023-12-22
• Last updated: 2023-12-22

Locations

1 site across 1 country: France